Fig. 10: Evaluation of in vivo efficacy of vaccine candidates for protection against Staphylococcus aureus infection. | Nature Communications

Fig. 10: Evaluation of in vivo efficacy of vaccine candidates for protection against Staphylococcus aureus infection.

From: Poly-β-D-(1,6)-N-acetyl-glucosamine (PNAG) glycan vaccines with broad spectrum neutralizing activities

Fig. 10

A Evaluation of non-acetylated PNAG-4mer-NH2 (DP4_NH2, 55), PNAG-8mer-NH2 (DP8 _NH2, 56). PNAG-12mer-NH2 (DP12_NH2, 57), and PNAG-18mer-NH2 (DP18 _NH2, 58); B evaluation of acetylated PNAG-4mer-45%NHAc (DP4_40%NHAc, 50), PNAG-8mer-40%NHAc (DP8_40%NHAc, 51), PNAG-12mer-45%NHAc (DP12_45%NHAc, 52), PNAG-12mer-60%NHAc (DP12_60%NHAc, 54), and PNAG-18mer-45%NHAc (DP18_45%NHAc, 53). Statistical analysis was performed using the two-sided Log-rank (Mantel-Cox) test in Kaplan-Meier survival analysis with GraphPad Prism version 10.4.0 for macOS. Comparisons were conducted pairwise; no multiple comparisons were performed.

Back to article page